Repatha
(Evolocumab)ApprovedMonoclonal antibody
AmgenEvolocumab is used to lower cholesterol levels in people who have high cholesterol or heart disease, helping to reduce the risk of heart attacks and strokes.[2] Repatha is currently approved and in use across 37 indications[4].[1]
Repatha is one of 742 biologic programs targeting Coronary Artery Disease. It is currently in Approved.
37
Indications
121
Total Trials
14
Active Trials
741
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 37 indications
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Repatha
AmgenApproved
Bnt162b2
BioNTechPreclinical
Stivarga
BayerPreclinical
Aldactone
PfizerPreclinical
Rayaldee
OOrganon and Co
Preclinical
Nadroparin
GSKPreclinical
Statins
SanofiPreclinical
Achromycin V
WWyeth-Lederle Vaccines
Preclinical
Orap
TevaPreclinical
HB-Admscs
HHope Biosciences Research Foundation
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Antibody6 trials
Cholesterol5 trials
Cardiovascular Disease5 trials
Acute Coronary Syndrome5 trials
Effect of Evolocumab Added to Moderate-Intensity Statin Therapy on LDL-C Lowering and Cardiovascular Adverse Events in Patients With Acute Coronary Syndrome
Unknown status·—·Phase 4·NCT04100434·500 enrolled
Familial Hypercholesterolemia5 trials
68 more indications
Hypercholesterolemia4 trials
Acute Myocardial Infarction3 trials
ESS3 trials
PCSK9 Inhibitor3 trials
PCSK9 Inhibitor Treatment for Patients With SPG5
Unknown status·FFirst Affiliated Hospital of Fujian Medical University·Phase 1/2·NCT04101643·30 enrolled
Coronary Artery Disease3 trials
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With High Risk Coronary Artery Disease (FORWARD)
Unknown status·—··NCT04087915·1,000 enrolled
Efficacy and Safety3 trials
Hyperlipidemia3 trials
Cardiovascular3 trials
Myocardial Infarction3 trials
Heart Disease2 trials
Ischemic stroke2 trials
Safety and Efficacy of Evolocumab in Ischemic Stroke
Unknown status·—·Phase 4·NCT05697185·200 enrolled
Drug Therapy2 trials
Efficacy2 trials
MPA2 trials
The Impact of Pcsk-9 Inhibition on PET CFR in Patients at High CV Risk
Recruiting·—·Phase 4·NCT05152888·50 enrolled
Monoclonal2 trials
Trial2 trials
Coronary Atherosclerosis2 trials
Effect of Evolocumab on Coronary Atherosclerosis
Completed·—·Phase 3·NCT03689946·55 enrolled
Metastatic NSCLC1 trial
Empagliflozin1 trial
Lip1 trial
Randomized1 trial
High-Resolution Assessment of Extracranial Plaques in a Multiple Centers Evolocumab Randomized Study
Unknown status·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 4·NCT05585151·200 enrolled
Asymptomatic Carotid Artery Stenosis1 trial
LDL-cholesterol1 trial
Impact of LDL-cholesterol Lowering on Platelet Activation
Terminated·—·Phase 4·NCT03331666·4 enrolled
End-Stage Renal Disease1 trial
TIA1 trial
Hypertriglyceridemia1 trial
Oral1 trial
COVID-191 trial
Surgical1 trial
The PCSK9i Inhibitor Evolocumab - a Surgical Trial of Pharamcodynamics and Kinetics Evaluation
Completed·—·Phase 1·NCT04937413·32 enrolled
Platelet Reactivity1 trial
Safety and Efficacy1 trial
Renal Transplant Recipients1 trial
Lipid Management in Renal Transplant Recipients Using Evolocumab.
Unknown status·—·Phase 4·NCT04608474·120 enrolled
Inflammation1 trial
Symptomatic Intracranial Atherosclerotic Stenosis1 trial
Evolocumab Added to Statin Therapy in Symptomatic Intracranial Atherosclerotic Stenosis (EAST-ICAS)
Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 3·NCT05741086·80 enrolled
Heart Failure1 trial
Diabetes Mellitus1 trial
Intravascular Ultrasound1 trial
Vascular Disease1 trial
Non-Small Cell Lung Cancer1 trial
Atherosclerotic Plaque1 trial
A Study of Evolocumab on Carotid Artery Atherosclerotic Plaque Morphology Prior to Carotid EndArterectomy
Unknown status·CCanadian Medical and Surgical Knowledge Translation Research Group·Phase 4·NCT04539223·60 enrolled
High Cardiovascular Risk1 trial
Cardiac Allograft Vasculopathy1 trial
Immunodeficiency1 trial
Renal Cell Carcinoma1 trial
Peripheral Arterial Disease1 trial
Homozygous Familial Hypercholesterolemia1 trial
Type 2 Diabetes1 trial
Coronary Artery Bypass1 trial
Acute Stroke1 trial
Carotid Artery Stenosis1 trial
Coronary Heart Disease1 trial
Regulatory
FDA Approval Timeline[5]
Aug 27, 2015
REPATHA
BLA BLA125522
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Repatha drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Evolocumab. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]